US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6300129B1
(en)
*
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
KR20050085971A
(en)
*
|
1995-04-27 |
2005-08-29 |
아브게닉스, 인크. |
Human antibodies derived from immunized xenomice
|
AU2008202860B9
(en)
*
|
1995-04-27 |
2012-03-29 |
Amgen Fremont Inc. |
Human Antibodies Derived From Immunized Xenomice
|
AU4376400A
(en)
*
|
1995-04-27 |
2000-11-30 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
AU2466895A
(en)
*
|
1995-04-28 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5919681A
(en)
*
|
1995-06-07 |
1999-07-06 |
Wohlstadter Jacob N |
Method for promoting enzyme diversity
|
US5914256A
(en)
*
|
1995-06-07 |
1999-06-22 |
Wohlstadter Jacob N |
Method for promoting enzyme diversity
|
JP4102435B2
(en)
*
|
1995-06-07 |
2008-06-18 |
ウオルスタドター,ジャコブ,エヌ. |
How to promote enzyme diversification
|
US6156541A
(en)
*
|
1995-07-21 |
2000-12-05 |
The Board Of Regents Of The University Of Nebraska |
Compositions and methods for catalyzing hydrolysis of HIV gp120
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6497878B1
(en)
|
1996-04-23 |
2002-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
|
JP2000510692A
(en)
|
1996-05-04 |
2000-08-22 |
ゼネカ リミテッド |
Monoclonal antibodies to CEA, conjugates comprising the antibodies, and their therapeutic use in ADEPT systems
|
AU2008200005B2
(en)
*
|
1996-12-03 |
2012-05-17 |
Amgen Fremont Inc. |
Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom
|
EP2314625B1
(en)
|
1996-12-03 |
2014-05-07 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
US6080910A
(en)
*
|
1997-02-20 |
2000-06-27 |
Case Western Reserve University |
Transgenic knockout animals lacking IgG3
|
ES2382488T3
(en)
|
1997-03-21 |
2012-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
A preventive or therapeutic agent for diseases mediated by sensitized t cells comprising an il-6 antagonist as an active ingredient
|
US8173127B2
(en)
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
GB9711167D0
(en)
*
|
1997-05-31 |
1997-07-23 |
Babraham The Inst |
Telomere-associated chromosome fragmentation
|
PT1004315E
(en)
|
1997-08-15 |
2008-07-09 |
Chugai Pharmaceutical Co Ltd |
Preventives and/or remedies containing anti-il-6 receptor neutralizing antibodies for reducing the excretion of urinary protein in systemic lupus erythematosus
|
GB9823930D0
(en)
*
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
ATE518949T1
(en)
|
1998-11-04 |
2011-08-15 |
Chugai Pharmaceutical Co Ltd |
NEW SERINE PROTEASES OF THE TRYPSIN FAMILY
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
EA006972B1
(en)
|
1998-12-23 |
2006-06-30 |
Пфайзер Инк. |
Human monoclonal antibodies to ctla-4 and methods for use thereof
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
AU3674000A
(en)
|
1999-04-09 |
2000-11-14 |
Chugai Research Institute For Molecular Medicine, Inc. |
Novel fetal genes
|
WO2000075314A1
(en)
|
1999-06-02 |
2000-12-14 |
Chugai Research Institute For Molecular Medicine, Inc. |
Novel hemopoietin receptor protein nr10
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
CA2382587A1
(en)
|
1999-08-23 |
2001-03-01 |
Chugai Seiyaku Kabushiki Kaisha |
Hm1.24 antigen expression potentiators
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
EP1792991A1
(en)
|
1999-08-24 |
2007-06-06 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
WO2001018200A1
(en)
|
1999-09-06 |
2001-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Tsg-like gene
|
AU7491800A
(en)
*
|
1999-09-15 |
2001-04-17 |
Therapeutic Human Polyclonals, Inc. |
Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
|
JP4838961B2
(en)
|
1999-09-21 |
2011-12-14 |
中外製薬株式会社 |
Transporter genes OATP-B, C, D, and E
|
KR20030008205A
(en)
|
1999-10-01 |
2003-01-24 |
추가이 세이야쿠 가부시키가이샤 |
Prevention and treatment of diseases associated with blood coagulation
|
DE60135971D1
(en)
|
2000-01-24 |
2008-11-13 |
Haruo Sugiyama |
WT1 INTERACTING PROTEIN, WTIP
|
EP1283057B2
(en)
|
2000-04-28 |
2012-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
JP3597140B2
(en)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
UA81743C2
(en)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
OA12589A
(en)
|
2001-01-05 |
2006-06-08 |
Abgenix Inc |
Antibodies to insulin-like growth factor i receptor.
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
CN1312181C
(en)
|
2001-02-12 |
2007-04-25 |
米德列斯公司 |
Human monoclonal antibodies to FC Alpha receptor (CD89)
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
ES2624547T3
(en)
|
2001-11-14 |
2017-07-14 |
Janssen Biotech, Inc. |
Anti il 6 antibodies, compositions, methods and uses
|
WO2003047336A2
(en)
|
2001-11-30 |
2003-06-12 |
Abgenix, Inc. |
TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
|
EP3960855A1
(en)
|
2001-12-28 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing proteins
|
MXPA04006490A
(en)
|
2002-01-09 |
2005-06-08 |
Medarex Inc |
Human monoclonal antibodies against cd30.
|
US20050118163A1
(en)
|
2002-02-14 |
2005-06-02 |
Hidefumi Mizushima |
Antibody-containing solution pharmaceuticals
|
AU2003213271B2
(en)
|
2002-02-25 |
2009-07-16 |
Genentech, Inc. |
Novel type-1 cytokine receptor GLM-R
|
US7666610B2
(en)
|
2002-03-29 |
2010-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Expressing transporters on viral envelopes
|
WO2004022597A1
(en)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody against blood-solubilized n-terminal peptide in gpc3
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
KR101086533B1
(en)
|
2002-05-24 |
2011-11-23 |
쉐링 코포레이션 |
Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it
|
CN101613405A
(en)
|
2002-06-06 |
2009-12-30 |
肿瘤疗法科学股份有限公司 |
Gene relevant and polypeptide with human colon carcinoma
|
CN100532549C
(en)
|
2002-06-06 |
2009-08-26 |
肿瘤疗法科学股份有限公司 |
Genes and polypeptides relating to human colon cancers
|
US20060058511A1
(en)
|
2002-08-27 |
2006-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing protein solution preparation
|
ES2626268T3
(en)
|
2002-09-11 |
2017-07-24 |
Chugai Seiyaku Kabushiki Kaisha |
Protein Purification Method
|
TW200418988A
(en)
|
2002-09-30 |
2004-10-01 |
Oncotherapy Science Inc |
Method for diagnosing prostate cancer
|
TW200413725A
(en)
|
2002-09-30 |
2004-08-01 |
Oncotherapy Science Inc |
Method for diagnosing non-small cell lung cancers
|
EP3284753B1
(en)
|
2002-10-17 |
2019-06-05 |
Genmab A/S |
Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
|
CN100572535C
(en)
|
2002-10-22 |
2009-12-23 |
卫材R&D管理有限公司 |
Specific expressed gene in the product dopaminergic neuron precursor cell after division stops
|
US7632935B2
(en)
|
2002-10-30 |
2009-12-15 |
Chungai Seiyaku Kabushiki Kaisha |
DNA encoding a mast cell-derived membrane protein
|
EP1578397B1
(en)
|
2002-11-15 |
2012-12-26 |
Genmab A/S |
Human monoclonal antibodies against cd25
|
WO2004050683A2
(en)
|
2002-12-02 |
2004-06-17 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
US7282568B2
(en)
|
2002-12-16 |
2007-10-16 |
Medarex, Inc. |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
EP3000886A1
(en)
|
2003-03-19 |
2016-03-30 |
Amgen Fremont Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
JP4705469B2
(en)
|
2003-05-28 |
2011-06-22 |
武田薬品工業株式会社 |
Anti-BAMBI antibody and diagnostic or therapeutic agent for colorectal cancer and liver cancer containing the same
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
EP1635763B1
(en)
|
2003-06-09 |
2012-08-08 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
EP2228445A1
(en)
|
2003-06-18 |
2010-09-15 |
Chugai Seiyaku Kabushiki Kaisha |
Fucose Transporter
|
BRPI0411803A
(en)
|
2003-06-27 |
2006-05-23 |
Abgenix Inc |
antibodies directed to epidermal growth factor receptor deletion mutants and their uses
|
WO2005047459A2
(en)
|
2003-08-04 |
2005-05-26 |
University Of Massachusetts |
Sars nucleic acids, proteins, antibodies, and uses thereof
|
MXPA06001353A
(en)
|
2003-08-08 |
2006-05-04 |
Abgenix Inc |
Antibodies directed to parathyroid hormone (pth) and uses thereof.
|
US20080153104A1
(en)
|
2003-08-08 |
2008-06-26 |
Hiroyuki Aburantai |
Gene Overexpressed in Cancer
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
AU2003271186A1
(en)
|
2003-10-14 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
US7642341B2
(en)
|
2003-12-18 |
2010-01-05 |
Merck Serono S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
|
EP1533617A1
(en)
|
2003-11-19 |
2005-05-25 |
RMF Dictagene S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
|
WO2005054467A1
(en)
|
2003-12-03 |
2005-06-16 |
Chugai Seiyaku Kabushiki Kaisha |
EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN β-ACTIN PROMOTER
|
JP4942487B2
(en)
|
2003-12-10 |
2012-05-30 |
メダレックス インコーポレーティッド |
IP-10 antibody and use thereof
|
PT1711207E
(en)
|
2003-12-10 |
2013-02-13 |
Medarex Inc |
Interferon alpha antibodies and their uses
|
WO2005056605A1
(en)
|
2003-12-12 |
2005-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibodies recognizing trimer receptor or higher
|
PL1766093T3
(en)
|
2004-02-06 |
2011-11-30 |
Univ Massachusetts |
Antibodies against clostridium difficile toxins and uses thereof
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
AU2005227313A1
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through V gene manipulation
|
EP2343384A3
(en)
|
2004-03-23 |
2012-01-04 |
Oncotherapy Science, Inc. |
Method for diagnosing non-small cell lung cancer
|
ES2403055T3
(en)
|
2004-04-13 |
2013-05-13 |
F. Hoffmann-La Roche Ag |
Anti-P-selectin antibodies
|
WO2005103081A2
(en)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
US8921528B2
(en)
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
AU2005258077C1
(en)
|
2004-06-21 |
2012-10-25 |
E. R. Squibb & Sons, L.L.C. |
Interferon alpha receptor 1 antibodies and their uses
|
EP2287195B1
(en)
|
2004-07-01 |
2019-05-15 |
Novo Nordisk A/S |
Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
|
CN111925445A
(en)
|
2004-07-09 |
2020-11-13 |
中外制药株式会社 |
Anti-glypican 3 antibody
|
US20080199437A1
(en)
|
2004-07-22 |
2008-08-21 |
Eisai Co., Ltd. |
Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers
|
TWI380996B
(en)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
KR20070083899A
(en)
|
2004-10-01 |
2007-08-24 |
메다렉스, 인코포레이티드 |
Methods of treating cd30 positive lymphomas
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
NZ554824A
(en)
|
2004-10-22 |
2010-10-29 |
Revivicor Inc |
Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
|
EP1824886B1
(en)
|
2004-11-17 |
2010-12-22 |
Amgen Inc. |
Fully human monoclonal antibodies to il-13
|
CA2589800A1
(en)
|
2004-12-02 |
2006-06-08 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
US7572444B2
(en)
|
2004-12-20 |
2009-08-11 |
Amgen Fremont Inc. |
Binding proteins specific for human matriptase
|
CN105085678B
(en)
|
2004-12-21 |
2019-05-07 |
阿斯利康公司 |
The antibody of angiopoietin-2 and its application
|
WO2006067847A1
(en)
|
2004-12-22 |
2006-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Method of preparing antibody by use of cell having its fucose transporter function inhibited
|
CA2590164A1
(en)
|
2005-01-26 |
2006-08-03 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
EP2295601A1
(en)
|
2005-02-10 |
2011-03-16 |
Oncotherapy Science, Inc. |
Method of diagnosing bladder cancer
|
WO2006089232A2
(en)
|
2005-02-18 |
2006-08-24 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking fucosyl residues
|
TWI406870B
(en)
|
2005-02-21 |
2013-09-01 |
Chugai Pharmaceutical Co Ltd |
A method of making a protein using hamster IGF-1
|
EP1862804B1
(en)
|
2005-03-14 |
2010-05-05 |
Link Genomics, Inc. |
Method for diagnosis of prostate cancer
|
CN112480257A
(en)
|
2005-03-23 |
2021-03-12 |
根马布股份公司 |
CD38 antibodies for the treatment of multiple myeloma
|
WO2006109592A1
(en)
|
2005-04-08 |
2006-10-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
JO3058B1
(en)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
Anti-IL-6 Antibodies,Compositions,Methods and uses
|
CN101213297B
(en)
|
2005-05-09 |
2013-02-13 |
小野药品工业株式会社 |
Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
CA2610987C
(en)
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
HUE042561T2
(en)
|
2005-06-30 |
2019-07-29 |
Janssen Biotech Inc |
Anti-IL-23 antibodies, compositions, methods and uses
|
KR101411165B1
(en)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
Human monoclonal antibodies to programmed death ligand 1(pd-l1)
|
WO2007013479A2
(en)
|
2005-07-27 |
2007-02-01 |
Oncotherapy Science, Inc. |
Genes and polypeptides relating to prostate cancers
|
KR20080039999A
(en)
|
2005-08-18 |
2008-05-07 |
젠맵 에이/에스 |
Therapy with cd4 binding peptides and radiation
|
WO2007038637A2
(en)
|
2005-09-26 |
2007-04-05 |
Medarex, Inc. |
Human monoclonal antibodies to cd70
|
ES2400520T3
(en)
|
2005-09-29 |
2013-04-10 |
Eisai R&D Management Co., Ltd. |
Adhesion molecule to T cells and antibody against the molecule
|
WO2007043641A1
(en)
|
2005-10-14 |
2007-04-19 |
Fukuoka University |
Inhibitor of transplanted islet dysfunction in islet transplantation
|
CA2625664C
(en)
|
2005-10-21 |
2016-01-05 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
RU2450830C2
(en)
|
2005-10-21 |
2012-05-20 |
Чугаи Сейяку Кабусики Кайся |
Agent for cardiopathy
|
CA2627309A1
(en)
|
2005-10-28 |
2007-05-03 |
Meiji Seika Kaisha, Ltd. |
Pseudomonas aeruginosa outer membrane protein pa5158
|
EP1957115B8
(en)
|
2005-11-10 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
JP5398987B2
(en)
|
2005-11-14 |
2014-01-29 |
セルミド リミテッド |
Method for treating and preventing diseases based on abnormal function of regulatory T cells
|
AR057582A1
(en)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
|
KR20080084818A
(en)
|
2005-11-25 |
2008-09-19 |
각고호우징 게이오기주크 |
Therapeutic agent for prostate cancer
|
EP1954311A4
(en)
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
Ctla-4 antibody dosage escalation regimens
|
AU2006321554B2
(en)
|
2005-12-08 |
2012-08-02 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1
|
EP1979001B1
(en)
|
2005-12-13 |
2012-04-11 |
Medimmune Limited |
Binding proteins specific for insulin-like growth factors and uses thereof
|
RU2008130898A
(en)
|
2005-12-28 |
2010-02-10 |
Асубио Фарма Ко., Лтд. (Jp) |
ANTI-BODY AGAINST PERIOSTINE AND CONTAINING ITS PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF A DISEASE IN THE DEVELOPMENT OF WHICH THE PERIOSTIN IS PARTICIPATED
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
AR056857A1
(en)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
|
DK2463305T3
(en)
|
2006-01-12 |
2016-08-29 |
Alexion Pharma Inc |
Antibodies to OX-2 / CD200 and uses thereof
|
US20090175886A1
(en)
|
2006-01-17 |
2009-07-09 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
|
CA2637917C
(en)
|
2006-01-27 |
2015-11-24 |
Keio University |
Therapeutic agents for diseases involving choroidal neovascularization
|
WO2007114340A1
(en)
|
2006-03-30 |
2007-10-11 |
Meiji Seika Kaisha, Ltd. |
Pseudomonas aeruginosa outer membrane protein pa0427
|
EP2003960B1
(en)
|
2006-03-31 |
2015-06-10 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
WO2007118214A2
(en)
|
2006-04-07 |
2007-10-18 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
JP5754875B2
(en)
|
2006-04-07 |
2015-07-29 |
国立大学法人大阪大学 |
Muscle regeneration promoter
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
WO2007129457A1
(en)
|
2006-04-25 |
2007-11-15 |
The University Of Tokyo |
Therapeutic agents for alzheimer's disease and cancer
|
KR101557603B1
(en)
|
2006-06-08 |
2015-10-06 |
추가이 세이야쿠 가부시키가이샤 |
Preventive or remedy for inflammatory disease
|
MX2008015975A
(en)
|
2006-06-14 |
2009-03-26 |
Chugai Pharmaceutical Co Ltd |
Hematopoietic stem cell proliferation promoter.
|
CA2657385A1
(en)
|
2006-07-13 |
2008-01-17 |
Naoki Kimura |
Cell death inducer
|
EP2574625B1
(en)
|
2006-07-21 |
2015-02-25 |
HuBit genomix, Inc. |
Remedy for renal disease
|
ES2746925T3
(en)
|
2006-08-03 |
2020-03-09 |
Medimmune Ltd |
Antibodies Directed Towards alfaVbeta6 and Use of Them
|
CL2007002225A1
(en)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
|
EP2050466B1
(en)
|
2006-08-14 |
2015-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
WO2008030611A2
(en)
|
2006-09-05 |
2008-03-13 |
Medarex, Inc. |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
WO2008032833A1
(en)
|
2006-09-14 |
2008-03-20 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
DK2081595T3
(en)
|
2006-09-26 |
2019-07-15 |
Genmab As |
ANTI-CD38 PLUS CORTICOSTEROID PLUS A NON-CORTICOSTEROID KEMOTERAPEUTIKA FOR TUMOR TREATMENT
|
US8007797B2
(en)
|
2006-09-28 |
2011-08-30 |
Merck Serono S.A. |
Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use
|
PT2486941T
(en)
|
2006-10-02 |
2017-05-30 |
Squibb & Sons Llc |
Human antibodies that bind cxcr4 and uses thereof
|
NZ576855A
(en)
|
2006-10-12 |
2012-08-31 |
Forerunner Pharma Res Co Ltd |
Diagnosis and treatment of cancer using anti-ereg antibody
|
EP2068922B1
(en)
|
2006-10-19 |
2012-06-27 |
CSL Limited |
Anti-il-13r alpha 1 antibodies and their uses thereof
|
EP2078731A4
(en)
|
2006-10-20 |
2012-08-01 |
Forerunner Pharma Res Co Ltd |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
EP2093237B1
(en)
|
2006-10-20 |
2015-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
|
AR063840A1
(en)
|
2006-11-15 |
2009-02-25 |
Medarex Inc |
MONOCLONAL HUMAN ANTIBODIES FOR BTLA AND METHODS OF USE
|
CN101626785A
(en)
|
2006-11-17 |
2010-01-13 |
财团法人阪大微生物病研究会 |
Nerve elongation promoter and elongation inhibitor
|
JP5398538B2
(en)
|
2006-12-01 |
2014-01-29 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
Human antibodies that bind to CD22 and uses thereof
|
CL2007003622A1
(en)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
|
MX2009006277A
(en)
|
2006-12-14 |
2009-07-24 |
Medarex Inc |
Human antibodies that bind cd70 and uses thereof.
|
EP2103628A4
(en)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
|
US20100111851A1
(en)
|
2007-01-05 |
2010-05-06 |
The University Of Tokyo |
Diagnosis and treatment of cancer by using anti-prg-3 antibody
|
CN104524567A
(en)
|
2007-01-16 |
2015-04-22 |
阿布维公司 |
Methods for treating psoriasis
|
CL2008000188A1
(en)
|
2007-01-23 |
2008-07-18 |
Chugai Pharmaceutical Co Ltd |
AGENT TO DELETE THE REACTION OF CHRONIC REJECTION THAT INCLUDES AS AN ACTIVE INGREDIENT AN IL-6 INHIBITOR; AND USE OF THE IL-6 INHIBITOR.
|
EP2119777A4
(en)
|
2007-02-09 |
2011-05-25 |
Eisai R&D Man Co Ltd |
Gaba neuron progenitor cell marker 65b13
|
JP5241518B2
(en)
|
2007-02-15 |
2013-07-17 |
国立大学法人九州大学 |
Interstitial lung disease therapeutic agent comprising anti-HMGB-1 antibody
|
WO2008100624A2
(en)
|
2007-02-16 |
2008-08-21 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against erbb3 and uses thereof
|
CN101679512A
(en)
|
2007-02-21 |
2010-03-24 |
马萨诸塞州大学 |
Anti-hepatitis c virus (HCV) people antibody and uses thereof
|
US8192740B2
(en)
|
2007-02-27 |
2012-06-05 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
|
CL2008000719A1
(en)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
|
GEP20146112B
(en)
|
2007-03-22 |
2014-06-25 |
Ucb Pharma Sa |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
|
ES2667863T3
(en)
|
2007-03-29 |
2018-05-14 |
Genmab A/S |
Bispecific antibodies and their production methods
|
FI20075278A0
(en)
|
2007-04-20 |
2007-04-20 |
Biotie Therapies Corp |
Novel completely human anti-VAP-1 monoclonal antibodies
|
JP5117765B2
(en)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
Tumor diagnostic agent for PET containing anti-ROBO1 antibody
|
CA2688275A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
EP2167669A2
(en)
|
2007-05-31 |
2010-03-31 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
CN101801407B
(en)
|
2007-06-05 |
2013-12-18 |
耶鲁大学 |
Inhibitors of receptor tyrosine kinases and methods of use thereof
|
EP2175016A4
(en)
|
2007-06-25 |
2012-03-28 |
Forerunner Pharma Res Co Ltd |
Anti-prominin-1 antibody having adcc activity or cdc activity
|
EP2168599B1
(en)
|
2007-06-27 |
2016-08-10 |
Osaka University |
Cancer remedy containing antibody against peptide encoded by exon-17 of periostin
|
US8536313B2
(en)
|
2007-07-10 |
2013-09-17 |
Shionogi & Co., Ltd. |
Monoclonal antibody having neutralizing activity against MMP13
|
EP2174667B1
(en)
|
2007-07-26 |
2017-01-04 |
Osaka University |
Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
|
DK2185719T3
(en)
|
2007-08-02 |
2014-02-17 |
Novimmune Sa |
ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
JP5588866B2
(en)
*
|
2007-08-10 |
2014-09-10 |
メダレックス エル.エル.シー. |
HCO 32 and HCO 27 and related examples
|
CN104356225B
(en)
|
2007-08-20 |
2018-02-13 |
肿瘤疗法科学股份有限公司 |
CDH3 peptides and the medicament containing CDH3 peptides
|
EP4032899A1
(en)
|
2007-08-20 |
2022-07-27 |
Oncotherapy Science, Inc. |
Foxm1 peptide and medicinal agent comprising the same
|
ES2537323T3
(en)
|
2007-08-20 |
2015-06-05 |
Oncotherapy Science, Inc. |
CDCA1 peptide and pharmaceutical agent comprising it
|
EP2185188B1
(en)
|
2007-08-22 |
2014-08-06 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
|
JOP20080381B1
(en)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
|
EP4248976A3
(en)
|
2007-08-23 |
2024-04-10 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
LT2769729T
(en)
|
2007-09-04 |
2019-05-10 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
SG187477A1
(en)
|
2007-09-26 |
2013-02-28 |
U3 Pharma Gmbh |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
US8529895B2
(en)
|
2007-10-02 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies
|
TWI489993B
(en)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
Compositions and methods of use for antibodies against sclerostin
|
BRPI0818674B1
(en)
|
2007-10-15 |
2023-01-17 |
Chugai Seiyaku Kabushiki Kaisha |
METHODS FOR THE PRODUCTION OF A WHOLE ANTIBODY OR A FRAGMENT THEREOF AND FOR THE PREPARATION OF DRUGS, AS WELL AS A RECOMBINANT VECTOR
|
CN101965365A
(en)
|
2007-10-19 |
2011-02-02 |
伊缪纳斯制药株式会社 |
Antibody capable of combining the soluble ass oligomer specifically and application thereof
|
DK2567709T3
(en)
|
2007-11-02 |
2018-03-12 |
Novartis Ag |
Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
|
EP2570137A3
(en)
|
2007-11-07 |
2013-08-21 |
Celldex Therapeutics, Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
CN103275227B
(en)
|
2007-11-12 |
2015-02-11 |
U3制药有限公司 |
AXL antibodies
|
JP5676107B2
(en)
|
2007-11-14 |
2015-02-25 |
中外製薬株式会社 |
Diagnosis and treatment of cancer using anti-GPR49 antibody
|
EP2853544A1
(en)
|
2007-11-15 |
2015-04-01 |
Chugai Seiyaku Kabushiki Kaisha |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
EP2236604B1
(en)
|
2007-12-05 |
2016-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-nr10 antibody and use thereof
|
BRPI0821145B8
(en)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
use of an anti-nr10 antibody as a preventive or therapeutic agent for pruritus
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
BRPI0821658B8
(en)
|
2007-12-14 |
2021-05-25 |
Novo Nordisk As |
human monoclonal antibody or an antigen-binding fragment thereof that binds to hnkg2d and its uses
|
JPWO2009081955A1
(en)
|
2007-12-25 |
2011-05-06 |
明治製菓株式会社 |
Pseudomonas aeruginosa type III secretion apparatus component protein PA1698
|
PE20091174A1
(en)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
|
PT2248826E
(en)
|
2008-01-10 |
2013-09-06 |
Shionogi & Co |
Antibody directed against pcrv
|
EP2241578B1
(en)
|
2008-01-11 |
2016-04-20 |
The University of Tokyo |
Anti-cldn6 antibody
|
WO2009092806A2
(en)
|
2008-01-25 |
2009-07-30 |
Aarhus Universitet |
Selective exosite inhibition of papp-a activity against igfbp-4
|
EP2650017A3
(en)
|
2008-02-05 |
2014-01-22 |
Bristol-Myers Squibb Company |
Alpha 5 - beta 1 antibodies and their uses
|
KR101616136B1
(en)
|
2008-02-08 |
2016-04-27 |
이무나스 파마 가부시키가이샤 |
Antibody capable of binding specifically to A-oligomer and use thereof
|
KR20100126515A
(en)
|
2008-03-18 |
2010-12-01 |
아보트 러보러터리즈 |
Methods for treating psoriasis
|
WO2009119794A1
(en)
|
2008-03-27 |
2009-10-01 |
タカラバイオ株式会社 |
Prophylactic/therapeutic agent for infectious disease
|
CL2009000647A1
(en)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
|
EP2283862B1
(en)
|
2008-06-02 |
2018-08-08 |
The University of Tokyo |
Combination treatment of cancer comprising anti-mfg-e8 antibody
|
EP2305306B1
(en)
|
2008-06-05 |
2016-02-10 |
National Cancer Center |
Neuroinvasion inhibitor
|
WO2009154025A1
(en)
|
2008-06-20 |
2009-12-23 |
国立大学法人岡山大学 |
ANTIBODY AGAINST OXIDIZED LDL/β2GPI COMPLEX AND USE OF THE SAME
|
MX356218B
(en)
|
2008-08-05 |
2018-05-18 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5.
|
EP2324852B1
(en)
|
2008-08-07 |
2015-07-08 |
Nagasaki University |
Therapeutic or prophylactic agent for generalized pain syndrome
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
KR20160116056A
(en)
|
2008-08-14 |
2016-10-06 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
Anti-il-12/il-23 antibodies
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
MX349463B
(en)
|
2008-09-26 |
2017-07-31 |
Univ Emory |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor.
|
KR102362774B1
(en)
|
2008-09-30 |
2022-02-15 |
아블렉시스, 엘엘씨 |
Non-human mammals for the production of chimeric antibodies
|
EP2348827B1
(en)
|
2008-10-27 |
2015-07-01 |
Revivicor, Inc. |
Immunocompromised ungulates
|
ES2940466T3
(en)
|
2008-11-10 |
2023-05-08 |
Alexion Pharma Inc |
Methods and compositions for treating complement-associated disorders
|
EP2373687B1
(en)
|
2008-12-03 |
2016-10-26 |
Genmab A/S |
Igg4 antibody variants having modifications in the constant region
|
US20110311450A1
(en)
|
2008-12-08 |
2011-12-22 |
Zurit Levine |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
UA109633C2
(en)
|
2008-12-09 |
2015-09-25 |
|
HUMAN ANTIBODY AGAINST TISSUE FACTOR
|
MX2011007660A
(en)
*
|
2008-12-18 |
2011-08-17 |
Kingdon Craig R |
Non-human transgenic animals expressing humanised antibodies and use therof.
|
EP2377921B1
(en)
|
2008-12-22 |
2016-04-13 |
Eisai R&D Management Co., Ltd. |
Method for obtaining pancreatic progenitor cell using neph3
|
EP2388320B1
(en)
|
2008-12-22 |
2017-02-15 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-hs6st2 antibodies and uses thereof
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
US9139647B2
(en)
|
2008-12-25 |
2015-09-22 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-TM4SF20 antibody
|
MX2011006908A
(en)
|
2008-12-26 |
2011-10-06 |
Univ Tokio |
Diagnosis and treatment of cancer using anti-lgr7 antibody.
|
KR101769160B1
(en)
|
2009-03-05 |
2017-08-17 |
옥스포드 바이오테라퓨틱스 리미티드 |
Fully human antibodies specific to cadm1
|
JP2010210772A
(en)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
Method of manufacturing liquid crystal display device
|
JPWO2010110346A1
(en)
|
2009-03-24 |
2012-10-04 |
独立行政法人理化学研究所 |
Leukemia stem cell marker
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
EP2416803B1
(en)
|
2009-04-08 |
2016-04-06 |
LipUm AB |
New methods for treatment of inflammatory diseases
|
WO2010119691A1
(en)
|
2009-04-16 |
2010-10-21 |
国立大学法人東京大学 |
Diagnosis and treatment of cancer using anti-tmprss11e antibody
|
JP5812418B2
(en)
|
2009-04-17 |
2015-11-11 |
イムナス・ファーマ株式会社 |
Antibody specifically binding to Aβ oligomer and use thereof
|
WO2010124113A1
(en)
|
2009-04-23 |
2010-10-28 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
NO2424895T3
(en)
|
2009-04-27 |
2018-02-03 |
|
|
CN102414223A
(en)
|
2009-04-27 |
2012-04-11 |
诺瓦提斯公司 |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
|
KR20120051603A
(en)
|
2009-05-01 |
2012-05-22 |
고쿠리츠다이가쿠호징 도쿄다이가쿠 |
Anti-cadherin antibody
|
US8435523B2
(en)
|
2009-05-04 |
2013-05-07 |
Abbott Research B.V. |
Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
|
PE20120815A1
(en)
|
2009-05-05 |
2012-07-08 |
Novimmune Sa |
ANTI IL-17F ANTIBODIES AND METHODS OF USE OF THEM
|
JP5808052B2
(en)
|
2009-05-29 |
2015-11-10 |
中外製薬株式会社 |
Pharmaceutical composition comprising antagonist of EGF family ligand as ingredient
|
WO2010151632A1
(en)
|
2009-06-25 |
2010-12-29 |
Bristol-Myers Squibb Company |
Protein purifacation by caprylic acid (octanoic acid ) precipitation
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
DK3028564T5
(en)
|
2009-07-08 |
2024-04-29 |
Kymab Ltd |
ANIMAL MODELS AND THERAPEUTIC MOLECULES
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
WO2011013786A1
(en)
|
2009-07-31 |
2011-02-03 |
Maeda Shin |
Cancer metastasis inhibitor
|
KR20120090037A
(en)
|
2009-07-31 |
2012-08-16 |
메다렉스, 인코포레이티드 |
Fully human antibodies to btla
|
US8613924B2
(en)
|
2009-08-06 |
2013-12-24 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to A beta oligomers and use thereof
|
ES2624835T3
(en)
|
2009-08-06 |
2017-07-17 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to the A beta oligomers and use thereof
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
AU2010285974A1
(en)
|
2009-08-17 |
2012-03-22 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
WO2011032148A1
(en)
|
2009-09-14 |
2011-03-17 |
Abbott Laboratories |
Methods for treating psoriasis
|
WO2011037983A1
(en)
|
2009-09-23 |
2011-03-31 |
Medarex, Inc. |
Cation exchange chromatography
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
EP2496604B1
(en)
|
2009-11-06 |
2017-08-23 |
IDEXX Laboratories, Inc. |
Canine anti-cd20 antibodies
|
WO2011057250A1
(en)
|
2009-11-09 |
2011-05-12 |
Alexion Pharmaceuticals, Inc. |
Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
|
CN102812045B
(en)
|
2009-11-13 |
2018-04-13 |
第一三共欧洲有限公司 |
For treating or preventing the material and method of human epidermal growth factor acceptor 3 (HER 3) relevant disease
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
RS56484B1
(en)
|
2009-11-17 |
2018-01-31 |
Squibb & Sons Llc |
Methods for enhanced protein production
|
MX343747B
(en)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Targeted binding agents against b7-h1.
|
EP2507265B1
(en)
|
2009-12-01 |
2016-05-11 |
Compugen Ltd. |
Antibody specific for heparanase splice variant T5 and its use.
|
JP6012473B2
(en)
|
2010-01-11 |
2016-10-25 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
Biomarker of immunomodulatory effect in human treatment with anti-CD200 antibody
|
TWI609698B
(en)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody-containing solution preparation
|
HUE056313T2
(en)
|
2010-01-29 |
2022-02-28 |
Chugai Pharmaceutical Co Ltd |
Anti-dll3 antibody
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
PT2505654T
(en)
*
|
2010-02-08 |
2016-11-18 |
Regeneron Pharma |
Common light chain mouse
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
JP5380553B2
(en)
|
2010-02-10 |
2014-01-08 |
富士フイルムRiファーマ株式会社 |
Radioactive metal-labeled anti-cadherin antibody
|
WO2011105573A1
(en)
|
2010-02-26 |
2011-09-01 |
株式会社未来創薬研究所 |
Anti-icam3 antibody and use thereof
|
JP5889181B2
(en)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
Antibody constant region variants
|
WO2011110642A2
(en)
|
2010-03-10 |
2011-09-15 |
Genmab A/S |
Monoclonal antibodies against c-met
|
SG183983A1
(en)
|
2010-03-17 |
2012-10-30 |
Abbott Res Bv |
Anti-nerve growth factor (ngf) antibody compositions
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CN107098958B
(en)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
VISTA regulatory T cell mediator protein, VISTA binding agent and uses thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
WO2011123708A2
(en)
|
2010-03-31 |
2011-10-06 |
Ablexis Llc |
Genetic engineering of non-human animals for the production of chimeric antibodies
|
WO2011130434A2
(en)
|
2010-04-13 |
2011-10-20 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
US9150663B2
(en)
|
2010-04-20 |
2015-10-06 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
SG185383A1
(en)
|
2010-04-30 |
2012-12-28 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
WO2011140254A1
(en)
|
2010-05-04 |
2011-11-10 |
Adimab, Llc |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
BR112012028326A2
(en)
|
2010-05-06 |
2017-03-21 |
Novartis Ag |
isolated multivalent antibody, isolated biparatopic antibodies, nucleic acid, vector, pharmaceutical composition, method of obtaining said antibodies and use thereof
|
US9428583B2
(en)
|
2010-05-06 |
2016-08-30 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
EP2575880B1
(en)
|
2010-05-27 |
2019-01-16 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
EP3539988A3
(en)
|
2010-05-27 |
2019-12-04 |
Genmab A/S |
Monoclonal antibodies against her2
|
JP5904552B2
(en)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
Pancreatic cancer treatment
|
EP2578231B1
(en)
|
2010-05-28 |
2022-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antitumor t cell response enhancer
|
WO2011154453A1
(en)
|
2010-06-09 |
2011-12-15 |
Genmab A/S |
Antibodies against human cd38
|
NO2582728T3
(en)
|
2010-06-15 |
2018-01-20 |
|
|
KR20130036276A
(en)
|
2010-06-22 |
2013-04-11 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
Antibodies to the c3d fragment of complement component 3
|
WO2011163401A2
(en)
|
2010-06-22 |
2011-12-29 |
Neogenix Oncology, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
WO2012005076A1
(en)
|
2010-07-08 |
2012-01-12 |
本田技研工業株式会社 |
High frequency heating coil
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
US10881084B2
(en)
|
2010-07-26 |
2021-01-05 |
Trianni, Inc |
Transgenic animals and methods of use
|
JP6146913B2
(en)
|
2010-08-02 |
2017-06-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Mice producing a binding protein containing a VL domain
|
CA2815154A1
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
ME02637B
(en)
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
KR101879885B1
(en)
|
2010-09-17 |
2018-07-18 |
박스알타 인코퍼레이티드 |
Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
|
WO2012035518A1
(en)
|
2010-09-17 |
2012-03-22 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
CA3182320A1
(en)
|
2010-09-23 |
2012-03-29 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
JP2013543384A
(en)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
Anti-IL12Rbeta1 antibody and its use in the treatment of autoimmune and inflammatory diseases
|
MX2013004679A
(en)
|
2010-10-25 |
2014-02-20 |
Univ Minnesota |
Therapeutic composition for treatment of glioblastoma.
|
EP3708586A1
(en)
|
2010-10-29 |
2020-09-16 |
Perseus Proteomics Inc. |
Anti-cdh3 antibody having high internalization capacity
|
MX355060B
(en)
|
2010-11-17 |
2018-04-03 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii.
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
CN103429737B
(en)
|
2010-11-30 |
2020-07-14 |
中外制药株式会社 |
Cytotoxic induction therapeutic agent
|
MX365235B
(en)
|
2010-11-30 |
2019-05-28 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly.
|
WO2012090939A1
(en)
|
2010-12-27 |
2012-07-05 |
国立大学法人名古屋大学 |
Method for suppressing receptor tyrosine kinase-mediated prosurvival signaling in cancer cells
|
SG192047A1
(en)
|
2011-01-24 |
2013-08-30 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
US9447187B2
(en)
|
2011-02-03 |
2016-09-20 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
CN103402542B
(en)
|
2011-02-28 |
2017-05-03 |
独立行政法人国立循环器病研究中心 |
Medicinal agent for inhibiting metastasis of malignant tumor
|
US8906635B2
(en)
|
2011-02-28 |
2014-12-09 |
Northshore University Healthsystem |
Methods of diagnosing Clostridium difficile infection
|
EP3825325A3
(en)
|
2011-03-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
MX356426B
(en)
|
2011-04-04 |
2018-05-29 |
Univ Iowa Res Found |
Methods of improving vaccine immunogenicity.
|
CA2831957A1
(en)
|
2011-04-07 |
2012-10-11 |
Amgen Inc. |
Novel egfr binding proteins
|
WO2012136552A1
(en)
|
2011-04-08 |
2012-10-11 |
H. Lundbeck A/S |
ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
CN103596974B
(en)
|
2011-04-15 |
2016-08-31 |
卡姆普根有限公司 |
Polypeptide and polynucleotide and for treating immunity related disorder and the purposes of cancer
|
US20140193420A1
(en)
|
2011-04-18 |
2014-07-10 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-itm2a antibody
|
WO2012143523A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
JOP20200043A1
(en)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
Methods of treating or preventing cholesterol related disorders
|
CN103842383B
(en)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
Polyspecific FAB fusion proteins and its application method
|
AU2012260601B2
(en)
|
2011-05-25 |
2018-02-01 |
Innate Pharma, S.A. |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
DK2728002T3
(en)
|
2011-06-30 |
2022-04-04 |
Chugai Pharmaceutical Co Ltd |
HETERODIMERIZED POLYPEPTIDE
|
EP2726503B1
(en)
|
2011-06-30 |
2019-09-04 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
JP6472999B2
(en)
|
2011-07-01 |
2019-02-20 |
ノバルティス アーゲー |
Methods for treating metabolic disorders
|
JP6454547B2
(en)
|
2011-07-06 |
2019-01-16 |
ゲンマブ エー/エス |
Regulation of complement-dependent cytotoxicity by modification of the C-terminus of antibody heavy chain
|
UA117901C2
(en)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Antibody variants and uses thereof
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
US9156911B2
(en)
|
2011-07-18 |
2015-10-13 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
WO2013012022A1
(en)
|
2011-07-19 |
2013-01-24 |
中外製薬株式会社 |
Stable protein-containing preparation containing argininamide or analogous compound thereof
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
WO2013017691A1
(en)
|
2011-08-04 |
2013-02-07 |
Medizinische Universität Innsbruck |
Cahgt1p inhibitors for use in the treatment of candidiasis
|
EP3865581A1
(en)
|
2011-08-05 |
2021-08-18 |
Regeneron Pharmaceuticals, Inc. |
Humanized universal light chain mice
|
EP2743699A4
(en)
|
2011-08-12 |
2015-04-08 |
Nat Inst Infectious Diseases |
Method for testing for, preventing, and treating infectious disease aspergillus fumigatus, and composition
|
WO2013027802A1
(en)
|
2011-08-23 |
2013-02-28 |
中外製薬株式会社 |
Novel anti-ddr1 antibody having anti-tumor activity
|
EP2749641B1
(en)
|
2011-09-07 |
2021-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell isolation
|
DK2757875T3
(en)
|
2011-09-19 |
2018-01-08 |
Kymab Ltd |
MANIPULATION OF IMMUNOGLOBULIN GENE DIVERSITY AND MULTI-ANTIBODY THERAPEUTICS
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
SG11201401101XA
(en)
|
2011-09-30 |
2014-08-28 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule for promoting loss of antigens
|
CA2850322C
(en)
|
2011-09-30 |
2023-10-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
WO2013046722A1
(en)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
Ion concentration-dependent binding molecule library
|
EP2765192A4
(en)
|
2011-10-05 |
2015-04-15 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
|
US9296826B2
(en)
|
2011-10-14 |
2016-03-29 |
Novartis Ag |
Antibodies and methods for WNT pathway-related diseases
|
EP2627773B1
(en)
|
2011-10-17 |
2017-06-14 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
EP2771364B1
(en)
|
2011-10-27 |
2019-05-22 |
Genmab A/S |
Production of heterodimeric proteins
|
JP6291254B2
(en)
|
2011-10-28 |
2018-03-14 |
中外製薬株式会社 |
Cancer stem cell specific molecule
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
EP2773667A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
EP2773665A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
EP2773664A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
KR20140091064A
(en)
|
2011-11-16 |
2014-07-18 |
암젠 인크 |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
US20150056182A1
(en)
|
2011-11-30 |
2015-02-26 |
Chugai Seiyaku Kabushiki Kaisha |
Drug containing carrier into cell for forming immune complex
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
CN104159924B
(en)
|
2011-12-05 |
2018-03-16 |
诺华股份有限公司 |
The antibody of EGF-R ELISA 3 (HER3)
|
TW201328707A
(en)
|
2011-12-05 |
2013-07-16 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
|
CN106831985A
(en)
|
2011-12-21 |
2017-06-13 |
诺华股份有限公司 |
The composition and method of the P factors are targeted for antibody
|
TWI593705B
(en)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
JP2015512616A
(en)
|
2012-02-01 |
2015-04-30 |
コンピュゲン エルティーディー. |
C1ORF32 antibody and its use for the treatment of cancer
|
DK2812443T3
(en)
|
2012-02-06 |
2019-08-26 |
Inhibrx Inc |
CD47 ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
TW202015731A
(en)
|
2012-02-24 |
2020-05-01 |
日商中外製藥股份有限公司 |
Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc[gamma]RIIB
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
WO2013147153A1
(en)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
Anti-lamp5 antibody and utilization thereof
|
CN104220595A
(en)
|
2012-04-04 |
2014-12-17 |
株式会社英仙蛋白质科学 |
Conjugate of anti-CDH3 (P-cadherin) antibody and drug
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
EA039663B1
(en)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
|
CN104470950B
(en)
|
2012-05-11 |
2017-04-26 |
公益财团法人微生物化学研究会 |
Anti-cxadr antibody
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
DK2857419T3
(en)
|
2012-05-30 |
2021-03-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule for the elimination of aggregated antigens
|
CA2874721A1
(en)
|
2012-05-30 |
2013-12-05 |
Tomoyuki Igawa |
Target tissue-specific antigen-binding molecule
|
WO2013184761A1
(en)
*
|
2012-06-05 |
2013-12-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for making fully human bispecific antibodies using a common light chain
|
BR112014031028A2
(en)
|
2012-06-11 |
2017-08-15 |
Amgen Inc |
ANTIGEN-BINDING PROTEIN ISOLATED, NUCLLEIC ACID ISOLATED, EXPRESSION VECTOR, HOST CELL, METHOD FOR PRODUCING AN ANTIGEN-BINDING PROTEIN, COMPOSITION, METHOD FOR REDUCING OR BLOCKING THE ACTIVITY OF MYOSTATIN, ACTIVIN A OR GDF-11, METHOD FOR ENHANCEMENT MUSCLE MASS FIRMNESS OR INCREASE THE MUSCLE MASS FIRMITY TO FAT MASS RATIO IN AN INDIVIDUAL IN NEED OF THE MENTIONED TREATMENT, METHOD FOR TREATMENT OR PREVENTION OF A HARMFUL DISEASE OF MUSCLE IN AN INDIVIDUAL SUFFERING FROM THE SAID DISORDER AND DUAL ANTAGONIST RECEPTOR ANTIBODY
|
SG11201407789RA
(en)
|
2012-06-12 |
2014-12-30 |
Regeneron Pharma |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
WO2013192504A1
(en)
|
2012-06-22 |
2013-12-27 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
AR091649A1
(en)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
EP2876160B1
(en)
|
2012-07-06 |
2020-05-13 |
Kyoto Prefectural Public University Corporation |
Differentiation marker for and differentiation control for ocular cells
|
CN104736174B
(en)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
Protein dimer with triple mutant
|
WO2014021339A1
(en)
|
2012-07-30 |
2014-02-06 |
国立大学法人名古屋大学 |
Monoclonal antibody against human midkine
|
EP3597747B1
(en)
|
2012-08-24 |
2023-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse fcgammarii-specific fc antibody
|
MX371442B
(en)
|
2012-08-24 |
2020-01-30 |
Chugai Pharmaceutical Co Ltd |
Fcyriib-specific fc region variant.
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
KR20150043523A
(en)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
Methods to control protein heterogeneity
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
JOP20200308A1
(en)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
IL-18 binding molecules
|
CN104797132B
(en)
|
2012-09-13 |
2017-06-30 |
中外制药株式会社 |
Gene knock-in non-human animal
|
EA031631B1
(en)
|
2012-09-27 |
2019-01-31 |
Чугаи Сеияку Кабушики Каиша |
Method for treating or preventing cancer, method for selecting a patient, method for testing cancer predisposition in a subject, fusion polypeptide and uses thereof
|
US11078518B2
(en)
|
2012-09-28 |
2021-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for evaluating blood coagulation reaction
|
HUE039920T2
(en)
|
2012-11-08 |
2019-02-28 |
Univ Miyazaki |
Antibody capable of specifically recognizing transferrin receptor
|
CA2886987C
(en)
|
2012-11-08 |
2022-07-12 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonists and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
MX368067B
(en)
|
2012-12-05 |
2019-09-18 |
Novartis Ag |
Compositions and methods for antibodies targeting epo.
|
KR20150095684A
(en)
|
2012-12-18 |
2015-08-21 |
노파르티스 아게 |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
WO2014104165A1
(en)
|
2012-12-27 |
2014-07-03 |
中外製薬株式会社 |
Heterodimerized polypeptide
|
ES2667333T3
(en)
|
2012-12-28 |
2018-05-10 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
KR20160007478A
(en)
|
2013-01-10 |
2016-01-20 |
젠맵 비. 브이 |
Human igg1 fc region variants and uses thereof
|
JO3519B1
(en)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
Antibody constructs for CDH19 and CD3
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
SG10201706383XA
(en)
|
2013-02-06 |
2017-09-28 |
Inhibrx Lp |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
EP2955226B1
(en)
|
2013-02-08 |
2019-06-26 |
Medical & Biological Laboratories Co., Ltd. |
Antibodies to human nrg1 protein
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
SG11201505330QA
(en)
|
2013-02-08 |
2015-08-28 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
AU2014218915B2
(en)
|
2013-02-20 |
2017-01-19 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
ES2673583T3
(en)
|
2013-02-28 |
2018-06-22 |
National Cancer Center |
Insoluble fibrin antibody
|
US10227396B2
(en)
|
2013-03-08 |
2019-03-12 |
Osaka University |
Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
JP2016514130A
(en)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Antibody against Notch3
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
ES2753950T3
(en)
|
2013-03-15 |
2020-04-15 |
Amgen Res Munich Gmbh |
Single-chain binding molecules comprising N-terminus ABP
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP3783017A1
(en)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
WO2014174596A1
(en)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
WO2014185550A1
(en)
|
2013-05-16 |
2014-11-20 |
Kyoto University |
Method for determining prognosis of cancer
|
US20160115237A1
(en)
|
2013-05-24 |
2016-04-28 |
The University Of British Columbia |
Cell senescence markers as diagnostic and therapeutic targets
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
AR096601A1
(en)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
|
BR112015032414A2
(en)
|
2013-06-24 |
2017-11-07 |
Chugai Pharmaceutical Co Ltd |
therapeutic agent comprising humanized antiepyrregulin antibody as active ingredient for non-small cell lung carcinoma excluding adenocarcinoma
|
JP6267792B2
(en)
|
2013-06-28 |
2018-01-24 |
アムジエン・インコーポレーテツド |
Methods for treating homozygous familial hypercholesterolemia
|
US10077304B2
(en)
|
2013-08-14 |
2018-09-18 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled receptor
|
TN2016000057A1
(en)
|
2013-08-14 |
2017-07-05 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
EP3042667A4
(en)
|
2013-09-04 |
2017-04-05 |
Osaka University |
Dpp-4-targeting vaccine for treating diabetes
|
WO2015041310A1
(en)
|
2013-09-20 |
2015-03-26 |
中外製薬株式会社 |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
EP3794941A1
(en)
|
2013-10-01 |
2021-03-24 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20160264648A1
(en)
|
2013-11-06 |
2016-09-15 |
Osaka University |
Antibody having broad neutralization activity against group 1 influenza a viruses
|
CN113278076A
(en)
|
2013-11-11 |
2021-08-20 |
中外制药株式会社 |
Antigen binding molecules comprising altered antibody variable regions
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
SG11201604495PA
(en)
|
2013-12-04 |
2016-07-28 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
|
HRP20220748T1
(en)
|
2013-12-24 |
2022-09-02 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
WO2015099167A1
(en)
|
2013-12-27 |
2015-07-02 |
国立大学法人大阪大学 |
Vaccine targeting il-17a
|
BR112016014824A2
(en)
|
2013-12-27 |
2017-09-19 |
Chugai Pharmaceutical Co Ltd |
METHOD TO PURIFY ANTIBODY THAT HAS A LOW ISOELECTRIC POINT
|
TW201609093A
(en)
|
2013-12-27 |
2016-03-16 |
Chugai Pharmaceutical Co Ltd |
Fgfr gatekeeper mutant gene and drug targeting same
|
DK3105252T3
(en)
|
2014-02-12 |
2019-10-14 |
Michael Uhlin |
BISPECIFIC ANTIBODIES FOR USE IN STEM CELL TRANSPLANTATION
|
EP3119194B1
(en)
|
2014-03-21 |
2021-04-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
CA2941514A1
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
SG10201808565QA
(en)
|
2014-03-31 |
2018-11-29 |
Debiopharm Int Sa |
Fgfr fusions
|
MX2016012873A
(en)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Humanized antibodies that bind lgr5.
|
TW201622746A
(en)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
Methods of improving or accelerating physical recovery after surgery for hip fracture
|
SI3151921T1
(en)
|
2014-06-06 |
2019-12-31 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CA2951885C
(en)
|
2014-06-11 |
2023-07-04 |
Kathy A. Green |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
TWI695011B
(en)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
Monoclonal antibodies against her2 epitope and methods of use thereof
|
TWI831106B
(en)
|
2014-06-20 |
2024-02-01 |
日商中外製藥股份有限公司 |
Pharmaceutical compositions for the prevention and/or treatment of diseases that develop and/or progress due to reduced or deficient activity of coagulation factor VIII and/or activated coagulation factor VIII
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
CN107073297B
(en)
|
2014-07-08 |
2021-09-14 |
纽约大学 |
Tau imaging ligands and their use in diagnosis and treatment of tauopathies
|
EA201790173A1
(en)
|
2014-07-11 |
2017-06-30 |
Генмаб А/С |
ANTIBODIES CONNECTING AXL
|
AR101669A1
(en)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
|
WO2016016859A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
TW201609811A
(en)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
Bispecific single chain antibody construct with enhanced tissue distribution
|
ES2726645T3
(en)
|
2014-08-01 |
2019-10-08 |
Inst Nat Sante Rech Med |
An anti-CD45RC antibody to use as a medicine
|
EP3194437B1
(en)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Angiopoietin-like 4 (angptl4) antibodies and methods of use
|
PE20170287A1
(en)
|
2014-08-07 |
2017-04-05 |
Novartis Ag |
ANTI-PROTEIN ANTIBODIES SIMILAR TO ANGIOPOYETIN 4 AND METHODS OF USE
|
EP4056993A1
(en)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring viscosity of protein solution
|
CA2963470A1
(en)
|
2014-10-03 |
2016-04-07 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
US10738078B2
(en)
|
2014-11-03 |
2020-08-11 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
AU2015343029B2
(en)
|
2014-11-05 |
2021-07-29 |
Annexon, Inc. |
Humanized anti-complement factor C1q antibodies and uses thereof
|
NZ731090A
(en)
|
2014-11-07 |
2024-03-22 |
F Hoffmann La Roche Ltd |
Improved il-6 antibodies
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
HUE050596T2
(en)
|
2014-11-21 |
2020-12-28 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
JP6738348B2
(en)
|
2014-12-19 |
2020-08-12 |
リジェネサンス ベスローテン フェンノートシャップ |
Antibodies that bind to human C6 and uses thereof
|
UY36449A
(en)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
|
AU2015369683C1
(en)
|
2014-12-23 |
2024-06-20 |
Bristol-Myers Squibb Company |
Antibodies to TIGIT
|
KR101892883B1
(en)
|
2015-02-27 |
2018-10-05 |
추가이 세이야쿠 가부시키가이샤 |
Composition for treating il-6-related diseases
|
EP3268100A1
(en)
|
2015-03-13 |
2018-01-17 |
Bristol-Myers Squibb Company |
Use of alkaline washes during chromatography to remove impurities
|
US11111314B2
(en)
|
2015-03-19 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
WO2016153983A1
(en)
|
2015-03-20 |
2016-09-29 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
US20180105554A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran sulfate to enhance protein a affinity chromatography
|
HUE061730T2
(en)
|
2015-04-17 |
2023-08-28 |
Amgen Res Munich Gmbh |
Bispecific antibody constructs for cdh3 and cd3
|
AU2016248817A1
(en)
|
2015-04-17 |
2017-08-17 |
F. Hoffmann-La Roche Ag |
Combination therapy with coagulation factors and multispecific antibodies
|
EP3584260A1
(en)
|
2015-04-28 |
2019-12-25 |
Mitsubishi Tanabe Pharma Corporation |
Rgma binding protein and use thereof
|
HRP20230060T1
(en)
|
2015-05-29 |
2023-03-17 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
JP2018522540A
(en)
|
2015-06-05 |
2018-08-16 |
ノバルティス アーゲー |
Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
|
DK3313882T3
(en)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antibodies and fragments
|
BR112017028353A2
(en)
|
2015-06-29 |
2018-09-04 |
The Rockfeller University |
cd40 antibodies with enhanced agonist activity
|
SI3319993T1
(en)
|
2015-07-10 |
2020-06-30 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
JO3711B1
(en)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
Antibodies specific for hyperphosphorylated tau and methods of use thereof
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
TWI793062B
(en)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for dll3 and cd3
|
TWI796283B
(en)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for msln and cd3
|
TWI744242B
(en)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for egfrviii and cd3
|
TWI829617B
(en)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for flt3 and cd3
|
TWI717375B
(en)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for cd70 and cd3
|
RU2752530C2
(en)
|
2015-08-03 |
2021-07-29 |
Новартис Аг |
Methods for treating fgf21-related disorders
|
FI3334761T3
(en)
|
2015-08-13 |
2023-08-14 |
Univ New York |
Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
JP6913078B2
(en)
|
2015-08-13 |
2021-08-04 |
ニューヨーク・ユニバーシティ |
Antibody-based molecules specific for the shortened Asp421 epitope of tau, and their use in the diagnosis and treatment of tau dysfunction.
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
KR20180042433A
(en)
|
2015-09-09 |
2018-04-25 |
노파르티스 아게 |
Use of thymus substrate lymphopoietin (TSLP) -binding antibodies and antibodies
|
JP6931329B2
(en)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
MX2018006072A
(en)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof.
|
FI3383920T3
(en)
|
2015-11-30 |
2024-04-10 |
Univ California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
EP3383903A1
(en)
|
2015-11-30 |
2018-10-10 |
Bristol-Myers Squibb Company |
Anti human ip-10 antibodies and their uses
|
US10813346B2
(en)
|
2015-12-03 |
2020-10-27 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
JP2019506844A
(en)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
Antibodies targeting CD32b and methods of use thereof
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
CR20180420A
(en)
|
2016-02-03 |
2018-12-05 |
Amgen Inc |
BIESPECTIFIC ANTIBODY CONSTRUCTS FOR BCMA AND CD3 THAT ARE LINKED TO T-CELLS
|
SI3411404T1
(en)
|
2016-02-03 |
2023-01-31 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
EA039859B1
(en)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Bispecific antibody constructs binding egfrviii and cd3
|
WO2017136734A1
(en)
|
2016-02-04 |
2017-08-10 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
US10899836B2
(en)
|
2016-02-12 |
2021-01-26 |
Janssen Pharmaceutica Nv |
Method of identifying anti-VISTA antibodies
|
EP3423489A1
(en)
|
2016-03-04 |
2019-01-09 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
US20190284293A1
(en)
|
2016-03-04 |
2019-09-19 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
TW202214700A
(en)
|
2016-03-14 |
2022-04-16 |
日商中外製藥股份有限公司 |
Cell injury inducing therapeutic drug for use in cancer therapy
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
EP4302782A3
(en)
|
2016-03-15 |
2024-03-27 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
KR20220004226A
(en)
|
2016-03-22 |
2022-01-11 |
바이오노믹스 리미티드 |
Administration of an anti-lgr5 monoclonal antibody
|
US10765724B2
(en)
|
2016-03-29 |
2020-09-08 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
US20210017281A1
(en)
|
2016-04-15 |
2021-01-21 |
Immunext, Inc. |
Anti-human vista antibodies and use thereof
|
CN109071665B
(en)
|
2016-04-18 |
2022-11-01 |
塞德斯医疗公司 |
Agonistic antibodies that bind human CD40 and uses thereof
|
JOP20170091B1
(en)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
|
KR102417687B1
(en)
|
2016-05-09 |
2022-07-07 |
브리스톨-마이어스 스큅 컴퍼니 |
TL1A antibodies and uses thereof
|
KR102492057B1
(en)
|
2016-06-15 |
2023-01-26 |
노파르티스 아게 |
Methods of treating diseases using inhibitors of bone morphogenetic protein 6 (BMP6)
|
PE20190227A1
(en)
|
2016-07-12 |
2019-02-13 |
H Lundbeck As |
SPECIFIC ANTIBODIES FOR HYPERPHOSPHORILATED TAU AND THEIR METHODS OF USE
|
TWI780057B
(en)
|
2016-07-14 |
2022-10-11 |
美商必治妥美雅史谷比公司 |
Antibodies against tim3 and uses thereof
|
CN109562153A
(en)
|
2016-08-07 |
2019-04-02 |
诺华股份有限公司 |
The immunization method that mRNA is mediated
|
CN109790201A
(en)
|
2016-08-12 |
2019-05-21 |
百时美施贵宝公司 |
Method for purifying proteins
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
CN109661241A
(en)
|
2016-09-06 |
2019-04-19 |
中外制药株式会社 |
Use the method for identification plasma thromboplastin component and/or the bispecific antibody of activated clotting factor IX and Stuart factor and/or activated clotting factor X
|
TW201825674A
(en)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
Oncolytic virus expressing bispecific engager molecules
|
CA3037961A1
(en)
|
2016-09-30 |
2018-04-05 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il23 specific antibody
|
AU2017343778A1
(en)
|
2016-10-13 |
2019-05-02 |
Massachusetts Institute Of Technology |
Antibodies that bind Zika virus envelope protein and uses thereof
|
WO2018087720A1
(en)
|
2016-11-14 |
2018-05-17 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
AR110074A1
(en)
|
2016-11-15 |
2019-02-20 |
H Lundbeck As |
AGENTS, USES AND METHODS FOR THE TREATMENT OF SINUCLEINOPATHY
|
JP2020502261A
(en)
|
2016-11-16 |
2020-01-23 |
ヤンセン バイオテツク,インコーポレーテツド |
Methods of treating psoriasis with anti-IL23 specific antibodies
|
KR102533814B1
(en)
|
2016-11-28 |
2023-05-19 |
추가이 세이야쿠 가부시키가이샤 |
Ligand-binding molecules capable of tunable ligand-binding activity
|
BR112018016717A2
(en)
|
2016-12-16 |
2018-12-26 |
H Lundbeck As |
agents, uses and methods
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
US11542337B2
(en)
|
2016-12-23 |
2023-01-03 |
Bristol Myers Squibb Company |
Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties
|
US10995137B2
(en)
|
2017-01-04 |
2021-05-04 |
H. Lundbeck A/S |
Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
|
WO2018129451A2
(en)
|
2017-01-09 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
KR20240038146A
(en)
|
2017-01-30 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
JOP20190189A1
(en)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
Low ph pharmaceutical composition comprising t cell engaging antibody constructs
|
CN110418652A
(en)
|
2017-02-07 |
2019-11-05 |
詹森生物科技公司 |
For treating the anti-TNF antibodies, composition and method of activity ankylosing spondylitis
|
US10899844B2
(en)
|
2017-02-08 |
2021-01-26 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
SG11201906947SA
(en)
|
2017-02-17 |
2019-08-27 |
Bristol Myers Squibb Co |
Antibodies to alpha-synuclein and uses thereof
|
WO2018174274A1
(en)
|
2017-03-24 |
2018-09-27 |
全薬工業株式会社 |
ANTI-IgM/B CELL SURFACE ANTIGEN BISPECIFIC ANTIBODY
|
US10982000B2
(en)
|
2017-03-24 |
2021-04-20 |
Novartis Ag |
Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody
|
US11359005B2
(en)
|
2017-03-30 |
2022-06-14 |
The Johns Hopkins University |
Supramolecular high affinity protein-binding system for purification of biomacromolecules
|
US20210107994A1
(en)
|
2017-03-31 |
2021-04-15 |
Public University Corporation Nara Medical University |
Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
|
TWI788340B
(en)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
Anti-icos agonist antibodies and uses thereof
|
EP3617316A4
(en)
|
2017-04-27 |
2020-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
Coagulation factor ix with improved pharmacokinetics
|
WO2018203545A1
(en)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
|
AR111773A1
(en)
|
2017-05-05 |
2019-08-21 |
Amgen Inc |
PHARMACEUTICAL COMPOSITION THAT INCLUDES CONSTRUCTS OF BISPECTIFIC ANTIBODIES FOR STORAGE AND ADMINISTRATION
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
AU2018292579A1
(en)
|
2017-06-28 |
2019-12-05 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
JP7379323B2
(en)
|
2017-08-18 |
2023-11-14 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
Supramolecular filament assembly for protein purification
|
TW201922780A
(en)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
|
WO2019078344A1
(en)
|
2017-10-20 |
2019-04-25 |
学校法人兵庫医科大学 |
Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
BR112020010248A2
(en)
|
2017-11-28 |
2020-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
ligand binding molecule having adjustable ligand binding activity
|
EA202091422A1
(en)
|
2017-12-11 |
2020-08-28 |
Эмджен Инк. |
METHOD FOR CONTINUOUS PRODUCTION OF PRODUCTS BASED ON BISPECIFIC ANTIBODIES
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
US11667713B2
(en)
|
2017-12-28 |
2023-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
UY38041A
(en)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
|
KR20200108870A
(en)
|
2018-01-12 |
2020-09-21 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibodies to TIM3 and uses thereof
|
JP2021510697A
(en)
|
2018-01-12 |
2021-04-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Combination therapy with anti-IL-8 antibody and anti-PD-1 antibody for cancer treatment
|
US20210363238A1
(en)
|
2018-01-31 |
2021-11-25 |
Motokazu Kato |
Therapeutic agent for asthma containing il-6 inhibitor
|
CA3092551A1
(en)
|
2018-03-05 |
2019-09-12 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
MX2020009861A
(en)
|
2018-03-23 |
2020-10-08 |
Bristol Myers Squibb Co |
Antibodies against mica and/or micb and uses thereof.
|
CN112313248A
(en)
|
2018-03-29 |
2021-02-02 |
百时美施贵宝公司 |
Method for purifying monomeric monoclonal antibodies
|
EA202092136A1
(en)
|
2018-05-07 |
2021-03-22 |
Генмаб А/С |
METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG
|
KR20210044183A
(en)
|
2018-05-07 |
2021-04-22 |
젠맵 에이/에스 |
Methods of treating cancer using a combination of anti-PD-1 antibody and anti-tissue factor antibody-drug conjugate
|
JP2021523138A
(en)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
How to treat depression with IL-23 antibody
|
CN112512480A
(en)
|
2018-05-21 |
2021-03-16 |
中外制药株式会社 |
Lyophilized preparation sealed in glass container
|
AR126019A1
(en)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
|
AU2019301336B2
(en)
|
2018-07-10 |
2022-11-24 |
Mitsubishi Tanabe Pharma Corporation |
Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
US20210301017A1
(en)
|
2018-07-30 |
2021-09-30 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
MA53330A
(en)
|
2018-08-03 |
2021-06-09 |
Amgen Inc |
ANTIBODY CONSTRUCTIONS FOR CLDN18.2 AND CD3
|
JP2021534779A
(en)
|
2018-08-27 |
2021-12-16 |
アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク |
Cryopreserved NK cells preloaded with antibody constructs
|
CA3153959A1
(en)
|
2018-09-18 |
2020-03-26 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
DK3883606T5
(en)
|
2018-09-24 |
2024-01-02 |
Janssen Biotech Inc |
SAFE AND EFFECTIVE METHOD FOR TREATMENT OF ULCERATIVE COLITIS WITH ANTI-IL12/IL23 ANTIBODY
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
UY38407A
(en)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
TREM2 STABILIZING ANTIBODIES
|
JP2022513386A
(en)
|
2018-10-30 |
2022-02-07 |
ゲンマブ エー/エス |
How to treat cancer with a combination of anti-VEGF antibody and anti-tissue factor antibody-drug conjugate
|
WO2020102501A1
(en)
|
2018-11-16 |
2020-05-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
KR20210093973A
(en)
|
2018-11-20 |
2021-07-28 |
얀센 바이오테크 인코포레이티드 |
A Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibodies
|
WO2020128864A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and effective method of treating lupus with anti-il12/il23 antibody
|
MX2021008537A
(en)
|
2019-01-15 |
2021-11-12 |
Janssen Biotech Inc |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis.
|
PE20212305A1
(en)
|
2019-01-22 |
2021-12-10 |
Bristol Myers Squibb Co |
ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES OF THESE
|
KR20210118878A
(en)
|
2019-01-23 |
2021-10-01 |
얀센 바이오테크 인코포레이티드 |
Anti-TNF antibody composition for use in a method of treating psoriatic arthritis
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
JP6821230B2
(en)
|
2019-02-04 |
2021-01-27 |
国立大学法人愛媛大学 |
How to make CAR library and scFv
|
WO2020175689A1
(en)
|
2019-02-28 |
2020-09-03 |
学校法人順天堂 |
Antibody capable of binding to truncated mutant calreticulin, and diagnostic, prophylactic or therapeutic drug for myeloproliferative neoplasms
|
WO2020180712A1
(en)
|
2019-03-01 |
2020-09-10 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
MA55282A
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
MANUFACTURING METHODS FOR THE PRODUCTION OF ANTI-TNF ANTIBODY COMPOSITIONS
|
JP2022526881A
(en)
|
2019-03-14 |
2022-05-27 |
ヤンセン バイオテツク,インコーポレーテツド |
Methods for Producing Anti-TNF Antibody Compositions
|
EP3938384A4
(en)
|
2019-03-14 |
2022-12-28 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
US20220153829A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
BR112021018441A2
(en)
|
2019-03-18 |
2023-02-28 |
Janssen Biotech Inc |
METHOD FOR TREATMENT OF PSORIASIS IN PEDIATRIC INDIVIDUALS WITH ANTI-IL12/IL23 ANTIBODY
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
JP2022527493A
(en)
|
2019-03-29 |
2022-06-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
How to measure the hydrophobicity of a chromatographic resin
|
CN113906042A
(en)
|
2019-04-10 |
2022-01-07 |
中外制药株式会社 |
Methods for purifying FC region modified antibodies
|
TW202110477A
(en)
|
2019-04-17 |
2021-03-16 |
國立大學法人廣島大學 |
Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
|
MX2021014302A
(en)
|
2019-05-23 |
2022-01-04 |
Janssen Biotech Inc |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha.
|
CA3142580A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
EP4023230A4
(en)
|
2019-06-05 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site-binding molecule
|
WO2020250159A1
(en)
|
2019-06-12 |
2020-12-17 |
Novartis Ag |
Natriuretic peptide receptor 1 antibodies and methods of use
|
TW202045711A
(en)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
Automated biomass-based perfusion control in the manufacturing of biologics
|
CA3148591A1
(en)
|
2019-07-26 |
2021-02-04 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
US20220306741A1
(en)
|
2019-09-10 |
2022-09-29 |
Amgen Inc. |
Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
|
TW202124446A
(en)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
Combination therapies with entpd2 antibodies
|
JP2022548881A
(en)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
|
MX2022005240A
(en)
|
2019-11-04 |
2022-08-19 |
Seagen Inc |
Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection.
|
TW202132343A
(en)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
TW202131954A
(en)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
CA3164996A1
(en)
|
2019-12-20 |
2021-06-14 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
CA3164129A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
AR120898A1
(en)
|
2019-12-26 |
2022-03-30 |
Univ Osaka |
AGENT TO TREAT OR PREVENT ACUTE NEUROMYELITIS OPTICA
|
EP4081554A1
(en)
|
2019-12-27 |
2022-11-02 |
Affimed GmbH |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
CA3168209A1
(en)
|
2020-01-15 |
2021-07-22 |
Osaka University |
Prophylactic or therapeutic agent for dementia
|
US20230055626A1
(en)
|
2020-01-15 |
2023-02-23 |
Osaka University |
Agent for prevention or treatment of diabetic autonomic neuropathy
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
EP4118113A1
(en)
|
2020-03-12 |
2023-01-18 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
AU2021240028A1
(en)
|
2020-03-19 |
2022-09-15 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
EP4129333A4
(en)
|
2020-03-27 |
2024-06-12 |
PhotoQ3 Inc. |
Pharmaceutical drug for destroying tumor cells
|
WO2021206078A1
(en)
|
2020-04-06 |
2021-10-14 |
株式会社PhotoQ3 |
Medicine for killing tumor cells
|
JP2023106635A
(en)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
US20230167193A1
(en)
|
2020-05-01 |
2023-06-01 |
Novartis Ag |
Immunoglobulin variants
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
JPWO2021235537A1
(en)
|
2020-05-22 |
2021-11-25 |
|
|
JP2023527972A
(en)
|
2020-05-29 |
2023-07-03 |
アムジエン・インコーポレーテツド |
Reduced Adverse Effect Administration of Bispecific Constructs that Bind CD33 and CD3
|
EP4174071A1
(en)
|
2020-06-24 |
2023-05-03 |
The University of Tokyo |
Photosensitizing dye
|
US20230263902A1
(en)
|
2020-06-29 |
2023-08-24 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
JPWO2022014703A1
(en)
|
2020-07-17 |
2022-01-20 |
|
|
TW202220694A
(en)
|
2020-07-28 |
2022-06-01 |
日商中外製藥股份有限公司 |
Prefilled syringe preparation with needle, provided with needle shield and including novel modified antibody
|
KR20230048059A
(en)
|
2020-07-31 |
2023-04-10 |
추가이 세이야쿠 가부시키가이샤 |
Pharmaceutical composition comprising cells expressing chimeric receptors
|
US11484604B2
(en)
|
2020-08-07 |
2022-11-01 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting CD46 and methods of use thereof
|
JPWO2022045247A1
(en)
|
2020-08-27 |
2022-03-03 |
|
|
EP4208259A2
(en)
|
2020-09-04 |
2023-07-12 |
NovaRock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
US20230365709A1
(en)
|
2020-10-08 |
2023-11-16 |
Affimed Gmbh |
Trispecific binders
|
TW202225188A
(en)
|
2020-11-06 |
2022-07-01 |
德商安美基研究(慕尼黑)公司 |
Polypeptide constructs binding to cd3
|
CN116323671A
(en)
|
2020-11-06 |
2023-06-23 |
安进公司 |
Multi-targeting bispecific antigen binding molecules with increased selectivity
|
JP2023547499A
(en)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
Antibody Fc variant
|
CA3199976A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Research (Munich) Gmbh |
Polypeptide constructs selectively binding to cldn6 and cd3
|
KR20230098335A
(en)
|
2020-11-06 |
2023-07-03 |
암젠 인크 |
Antigen binding domains with reduced clipping ratio
|
MX2023005528A
(en)
|
2020-11-17 |
2023-06-23 |
Seagen Inc |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody.
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
AR124914A1
(en)
|
2021-02-18 |
2023-05-17 |
Mitsubishi Tanabe Pharma Corp |
NEW ANTI-PAD4 ANTIBODY
|
US20220298236A1
(en)
|
2021-03-12 |
2022-09-22 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
|
CN117320749A
(en)
|
2021-03-12 |
2023-12-29 |
中外制药株式会社 |
Pharmaceutical composition for treating or preventing myasthenia gravis
|
EP4305062A1
(en)
|
2021-03-12 |
2024-01-17 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
WO2022212831A1
(en)
|
2021-04-02 |
2022-10-06 |
Amgen Inc. |
Mageb2 binding constructs
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
IL309996A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Manufacturing methods for producing anti-tnf antibody compositions
|
CN117916260A
(en)
|
2021-07-09 |
2024-04-19 |
詹森生物科技公司 |
Methods of manufacture for preparing anti-IL 12/IL23 antibody compositions
|
AU2022306144A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
WO2023007023A1
(en)
|
2021-07-30 |
2023-02-02 |
Affimed Gmbh |
Duplexbodies
|
WO2023048231A1
(en)
|
2021-09-24 |
2023-03-30 |
株式会社PhotoQ3 |
Medicine for killing tumor cells
|
CN118043031A
(en)
|
2021-10-04 |
2024-05-14 |
诺华股份有限公司 |
Surfactant stabilizers
|
JPWO2023058723A1
(en)
|
2021-10-08 |
2023-04-13 |
|
|
AU2022377628A1
(en)
|
2021-10-29 |
2024-04-11 |
Seagen Inc. |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
|
KR20240099352A
(en)
|
2021-10-29 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
How to Treat Crohn's Disease with Anti-IL23 Specific Antibodies
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
AU2022388887A1
(en)
|
2021-11-15 |
2024-07-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
TW202408583A
(en)
|
2022-05-06 |
2024-03-01 |
丹麥商珍美寶股份有限公司 |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024110898A1
(en)
|
2022-11-22 |
2024-05-30 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2024127366A1
(en)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|